MONTREAL, Nov. 28, 2012 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)
announced today that Ryan Weldon and
Jason Hanson will be named to
Valeant's Executive Management Team. Mr. Weldon will assume
the role of Executive Vice President/Company Group Chairman where
he will lead the U.S. Dermatology operations, including
prescription dermatology, aesthetics and podiatry. Mr. Weldon will
be relocating to Arizona where
these operations will be headquartered. Mr. Hanson will
relocate to New Jersey where he
will assume the role of Executive Vice President/Company Group
Chairman and lead certain U.S and international businesses and
functions to be named later. In addition, Vince Ippolito will be appointed Senior Vice
President, General Manager, Aesthetics and Justin Smith will be appointed Senior Vice
President, General Manager U.S. Rx Dermatology and both will report
to Ryan Weldon in Scottsdale, AZ. Mr. Ippolito and Mr.
Smith have each held various sales and marketing leadership
positions at Medicis Pharmaceutical Corporation (NYSE: MRX). These
changes will be effective upon the close of Valeant's acquisition
of Medicis, currently anticipated to occur on December 11, 2012.
"The Board of Directors and I are pleased to add such
experienced candidates to the Valeant management team," said
J. Michael Pearson, chairman and
chief executive officer. "These individuals have demonstrated
exceptional operating performance at their respective companies and
business units and I believe they are the right candidates to
continue Valeant's growth and success in the future. We expect to
be able to announce more management announcements around the time
of closing."
Ryan Weldon has served as Vice
President & General Manager, Aesthetics since December 2011 and Vice President & General
Manager, Neurology & Other since January
2010. Mr. Weldon joined Valeant in 2008 after working for
McKinsey & Co. and Johnson & Johnson.
Jason Hanson has served as
Executive Vice President, Chief Operating Officer of Medicis
Pharmaceutical Corporation since July
2010, and as Executive Vice President since 2006. Mr. Hanson
joined Medicis in 2006 and was appointed to the position of
Executive Vice President, General Counsel, and Corporate Secretary.
From April 2004 to July 2006, Mr. Hanson served as General Counsel
for GE Healthcare Technologies, a global business specializing in
medical imaging, information technology and other durable medical
equipment and services, where he was responsible for the global
legal affairs of GE Healthcare Technologies and a member of the
company's senior management team.
Vince Ippolito has been with
Medicis for ten years where he most recently served as Executive
Vice President, Sales and Marketing. During his tenure at Medicis,
he has helped launch more than ten new products, including LOPROX®
Shampoo, VANOS®, Restylane®, Perlane®, SOLODYN®,
ZIANA® and DYSPORT®. Prior to joining Medicis, Mr. Ippolito was
employed by Novartis AG.
Justin Smith has been with
Medicis for fifteen years where he most recently served as Senior
Vice President, Marketing for both dermatology and aesthetics
products. Most recently, Mr. Smith spearheaded Medicis'
access solutions strategy and was responsible for launching
SOLODYN®. He also held senior positions in sales
management.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of neurology, dermatology and branded
generics. More information about Valeant Pharmaceuticals
International, Inc. can be found at www.valeant.com.
Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements relate to, among other things, the
closing of the Medicis transaction and the future roles of certain
management. Forward-looking statements can generally be identified
by the use of words such as "believe," "anticipate," "expect,"
"estimate," "intend," "continue," "plan," "project," "will," "may,"
"should," "could," "would," "target," "potential," and other
similar expressions. In addition, any statements that refer
to expectations, projections or other characterizations of future
events or circumstances are forward-looking statements.
Actual results may differ materially from those expressed or
implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things, the satisfaction of customary closing
conditions with respect to the closing of the Medicis transaction,
and the risk factors as detailed from time to time in Valeant's
reports filed with the Securities and Exchange Commission and the
Canadian Securities Administrators.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
(Logo:
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)
SOURCE Valeant Pharmaceuticals International, Inc.
